The global KRAS inhibitors market size accounted for USD 112.71 million in 2024, grew to USD 118.26 million in 2025 and is projected to surpass around USD 182.36 million by 2034, representing a healthy CAGR of 4.93% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: KRAS Inhibitors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. KRAS Inhibitors Market Revenue and Volume, by Cancer Type, 2024-2034
8.1.1. Lung Cancer
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Pancreatic Cancer
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1. KRAS Inhibitors Market Revenue and Volume, by End-Use, 2024-2034
9.1.1. Clinic Laboratories
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Cancer Diagnostic Centers
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Hospitals
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Cancer Research Institutes
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Academic Institutions
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)
11.1. Amgen
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boehringer Ingelheim
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. BridgeBio Pharma
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Erasca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Innovent Biologics, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Incyte
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Mirati Therapeutics
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Novartis
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Jemincare
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Cardiff Oncology, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample